Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a definitive agreement to acquire a 51% stake in Charging Robotics, an intelligent EV (electric vehicles) wireless charging solutions for automated parking systems and autonomous mobile platforms company.
Charging Robotics develops dedicated intelligent wireless charging systems designed specifically for automated parking facilities, autonomous mobile platforms, and robotaxi operations, environments where conventional cables and plug-in infrastructure cannot operate.
Its proprietary technology delivers continuous charging of up to 10 kW, with smart vehicle communication and dynamic energy management that allocates power in real time. The system integrates directly into robotic parking platforms and autonomous vehicle workflows, requiring no manual connection and no traditional charging stations.
“The technology,” reads this morning’s news release, “is designed to make EV charging a background function of smart parking and autonomous mobility, improving utilization, safety, and the end-user experience in dense urban settings.”
Under the terms of the Agreement, Clearmind will acquire the majority stake of Charging Robotics for an aggregate purchase price of $2.5 million. In addition, in connection with and as a condition to the closing of the Acquisition, the Company shall extend a loan to Charging Robotics in the principal amount of $1.5 million. The Loan shall bear interest at a rate of 4% per annum.
CMND shares let go of 24 cents, or 14.1%, to $1.46.
